In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.
In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).
Skin sensitivity will be a factor in vehicles for new treatments.
Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.
The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.
Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.
Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.
Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.
Factors ranging from demographics to the COVID-19 pandemic are shifting the landscape of occupational dermatoses.